Treatment of adynamic bone disease in a haemodialysis patient with teriparatide.
Clin Kidney J
; 8(2): 188-90, 2015 Apr.
Article
en En
| MEDLINE
| ID: mdl-25815175
ABSTRACT
Prevalence of adynamic bone disease (ABD), characterized by low bone turnover and absence or a reduced number of osteoblasts and osteoclasts, is increasing steadily over the last years. We present a dialysis patient, with recurrent bone fractures and biopsy-proven ABD, who was treated with teriparatide. Nine months after initiation of treatment, iPTH plasma levels increased to 520 pg/mL and a second bone biopsy revealed high bone turnover, normal mineralization and normal bone volume. Two years later, iPTH was 250-350 pg/dL and bone metabolism parameters within normal range. The probable utility of teriparatide in the treatment of ABD in dialysis patients is discussed.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
Clin Kidney J
Año:
2015
Tipo del documento:
Article
País de afiliación:
Grecia